Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Interpace Biosciences's Equity-to-Asset or its related term are showing as below:
IDXGD'
s Equity-to-Asset Range Over the Past 10 Years
Min: -5.04 Med: -0.04 Max: 0.75
Current: 0.67
During the past 13 years, the highest Equity to Asset Ratio of Interpace Biosciences was 0.75. The lowest was -5.04. And the median was -0.04.
IDXGD's Equity-to-Asset is ranked better than 61.9% of 210
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.595
vs IDXGD: 0.67
Equity to Asset ratio can vary greatly across different industries, as they have different capital structure. A company with smaller Equity to Asset ratio (more leveraged) may have higher ROE % because of the leverage.
For banks, the required minimum Equity to Asset ratio by regulation is 5%. Some stronger banks may have Equity to Asset Ratio of more than 10%.
Interpace Biosciences Equity-to-Asset Related Terms
Interpace Biosciences Equity-to-Asset Historical Data
* Premium members only.
The historical data trend for Interpace Biosciences's Equity-to-Asset can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IDXGD vs PRPO, ADVB, BIOQ: Equity-to-Asset Comparison
For the Diagnostics & Research subindustry, Interpace Biosciences's Equity-to-Asset, along with its competitors' market caps and Equity-to-Asset data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Interpace Biosciences Equity-to-Asset vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Interpace Biosciences's Equity-to-Asset distribution charts can be found below:
* The bar in red indicates where Interpace Biosciences's Equity-to-Asset falls into.
Equity to Asset ratio measures the ratios of the portion of the asset owned by shareholders out of the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.
Equity to Asset ratio is calculated by dividing total stockholders equity by total asset.
Interpace Biosciences's Equity to Asset Ratio for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Interpace Biosciences (IDXGD) has a Equity-to-Asset of 0.67 as of Jun. 2026. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Interpace Biosciences and its competitors. According to the industry distribution chart, Interpace Biosciences ranks #80 out of 210 companies in the Medical Diagnostics & Research industry, placing it in the top 38.1%.
Is Interpace Biosciences' Equity-to-Asset too high?
Interpace Biosciences' current Equity-to-Asset is 0.67. The Medical Diagnostics & Research industry median Equity-to-Asset is 0.60. Interpace Biosciences' value of 0.67 is 12.6% above this industry median. Based on the distribution chart, Interpace Biosciences ranks #80 out of 210 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Interpace Biosciences has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Interpace Biosciences' Equity-to-Asset compare to PRPO and ADVB?
According to the Medical Diagnostics & Research industry distribution chart, Interpace Biosciences ranks #80 out of 210 companies for Equity-to-Asset. This puts Interpace Biosciences in the upper half of its industry. The industry median Equity-to-Asset is 0.60. Interpace Biosciences' value of 0.67 is 12.6% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Equity-to-Asset for a Medical Diagnostics & Research company?
The median Equity-to-Asset among Medical Diagnostics & Research companies is 0.60, based on 210 companies in the industry. Companies in the top quartile (top 25%) have a Equity-to-Asset significantly above this median, while those in the bottom quartile fall well below. However, Equity-to-Asset should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Interpace Biosciences's current Equity-to-Asset of 0.67 is 12.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Equity-to-Asset mean?
A high Equity-to-Asset can signal that a stock is expensive relative to its fundamentals. Equity-to-asset ratio equals total company equity divided by total assets. It measures financial leverage. View historical data on Interpace Biosciences and its competitors. For the Medical Diagnostics & Research industry, the median Equity-to-Asset is 0.60 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Interpace Biosciences's current Equity-to-Asset is 0.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Interpace Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Interpace Biosciences (IDXGD) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.20, compared to a current price of $7.62 — trading 3709% above its estimated fair value. The current Equity-to-Asset is 0.67 and 12.6% above the Medical Diagnostics & Research industry median of 0.60. Interpace Biosciences' overall GF Score™ is 41/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Equity-to-Asset calculated?
Equity-to-Asset is calculated from a company's financial statements. For Interpace Biosciences (IDXGD), the current Equity-to-Asset is 0.67 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Interpace Biosciences (IDXGD) Overvalued in 2026?
Based on GuruFocus' analysis, Interpace Biosciences stock appears to be overvalued.
The current stock price of $7.62 is trading 3709% above its estimated GF Value™ of $0.20.
GuruFocus considers Interpace Biosciences to be Significantly Overvalued.
Key valuation signals for IDXGD:
Equity-to-Asset: 0.67
GF Value™: $0.20 vs. price of $7.62 (3709% above fair value)
Industry Position: 12.6% above the Medical Diagnostics & Research median (#80 of 210)
No single metric tells the full story. See the IDXGD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Interpace Biosciences Inc provides esoteric molecular diagnostic testing and pathology services to aid physicians in evaluating cancer risk in patients with indeterminate biopsies and a perceived high risk of cancer based on clinical features. The company develops and commercializes genomic tests and related first-line assays that can personalize medicine and help improve patient diagnosis and management. Its clinical customers mainly consist of physicians, hospitals, cancer centers, commercial laboratories, pathology groups, and clinics. The various diagnostic tests offered by the company include ThyGeNEXT and ThyraMIRv2 for the detection of thyroid cancer.
41GF Score
Get the complete analysis for IDXGD
Equity-to-Asset is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IDXGD has been successfully added to your 
